FibroBiologics Inc (FBLG) ニュース

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a...

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and...

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a...

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

Form 8-K - Current report

FibroBiologics Engages Southern Star Research as CRO in Australia

HOUSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology

HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities